zolbetuximab
astellas
[]
#gi23 oral abstract session a starting now
claudin 18.2 getting lots of air time today. spotlight trial: zolbetuximab + mfolfox vs. pbo + mfolfox in pts with mg/gej adeno cldn18.2+ met primary ep: pfs benefit 10.6 mo vs 8.7 mo 
Oncologist | Focus on #NETs | she/her 
Division Chief, GI Oncology @YaleCancer | Consultant Editor @JCO_ASCO |
Tweets mine | ASCO FCOI: https://t.co/UuqIAQ54sX